What do primary care providers need to know about diabetes, atrial fibrillation, and heart failure? Dr. Matthew Freeby will address topics related to current type 2 diabetes care, with focus on education, medications and newer technologies. Dr. Karol Watson will discuss treatment and prevention of atrial fibrillation, and Dr. Jon Kobashigawa will discuss common questions about heart failure including risk factors, treatment options, lifestyle changes and prevention.
Heart failure is a global pandemic that continues to increase in prevalence. Despite the availability of established and novel therapies, mortality and morbidity in heart failure remains high. Join us for this overview of heart failure classification and pathophysiology, the evidence base supporting various treatments, and current guideline recommendations. Despite being the most common sustained arrhythmia in practice, the ideal management strategy for atrial fibrillation remains elusive for many clinicians. Accordingly, this session will review the classification and initial workup of patients with atrial fibrillation, with further discussion of the primary treatment goals. Stroke prevention therapies will be reviewed, along with means to achieve rate and rhythm control. Tune in to learn about ongoing gaps in the care of patients with heart failure and/or atrial fibrillation and how a standardized approach can help improve outcomes.
In recent years, promising evidence has emerged for new pharmacologic treatments for heart failure with reduced ejection fraction (HFrEF); however, gaps in clinician prescribing for the current guideline-directed therapies still exist. Join cardiology experts Ty Gluckman, MD, and Alison Bailey, MD, as they review the current recommendations for guideline-directed medical therapy in HFrEF, discuss strategies for implementing it, and assess the evidence for new and emerging treatments for HFrEF and recently approved agents, including SGLT2 inhibitors, vericiguat, and omecamtiv mecarbil.
Peripheral artery disease affects nearly 9 million Americans and is associated with significantly increased risk of cardiovascular morbidity and mortality. Beyond initiation of therapies to reduce cardiovascular risk, many interventions used to treat peripheral artery disease aim to improve functional status and quality of life. Join us for this overview, where we'll review the epidemiology, classification, evaluation and treatment of this condition. Heart failure is a global pandemic that continues to increase in prevalence. Despite the availability of established and novel therapies, mortality and morbidity in heart failure remains high. Join us for this overview of heart failure classification and pathophysiology, the evidence base supporting various treatments, and current guideline recommendations.
Refresh your skills in managing common cardiovascular conditions in your primary care patient population during this session. Cardiology specialist Ty Gluckman, MD, will review important updates and considerations for managing your patients with hypertension, hypercholesterolemia and heart failure.
Join cardiologist Ty Gluckman, MD in part two of this two-part podcast series as he reviews the unmet needs of patients with heart failure with reduced ejection fraction (HFrEF) and discusses the evidence on emerging pharmacologic treatments for HFrEF. He will describe the current data in HFrEF for the following drug classes: SGLT2 inhibitors, soluble guanylate cyclase stimulators, and selective cardiac myosin activators.